These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2941289)

  • 1. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Follath F; Bindschedler M; Wenk M; Frei R; Stalder H; Reber H
    Eur J Clin Microbiol; 1986 Apr; 5(2):236-40. PubMed ID: 2941289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa.
    Bayer AS; Kim KS
    Chemotherapy; 1986; 32(4):364-73. PubMed ID: 2942342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Giamarellou H; Galanakis N; Dendrinos C; Stefanou J; Daphnis E; Daikos GK
    Eur J Clin Microbiol; 1986 Apr; 5(2):232-5. PubMed ID: 2941288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.
    Scully BE; Neu HC; Parry MF; Mandell W
    Lancet; 1986 Apr; 1(8485):819-22. PubMed ID: 2870313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.
    Strunk RW; Gratz JC; Maserati R; Scheld WM
    Antimicrob Agents Chemother; 1985 Sep; 28(3):428-32. PubMed ID: 2934021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.
    Haller I
    Antimicrob Agents Chemother; 1985 Nov; 28(5):663-6. PubMed ID: 2936301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
    Bayer AS; Blomquist IK; Kim KS
    J Antimicrob Chemother; 1986 May; 17(5):641-9. PubMed ID: 2941403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.
    Chin NX; Jules K; Neu HC
    Eur J Clin Microbiol; 1986 Feb; 5(1):23-8. PubMed ID: 2938945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.
    Johnson M; Miniter P; Andriole VT
    J Infect Dis; 1987 Apr; 155(4):783-8. PubMed ID: 3102631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa.
    Thauvin C; Lecomte F; Le Boete I; Grise G; Lemeland JF
    Infection; 1989; 17(1):31-4. PubMed ID: 2493429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
    Rubio TT; Shapiro C
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():147-52. PubMed ID: 3100490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with ciprofloxacin in the treatment of various infections caused mainly by Pseudomonas aeruginosa.
    Giamarellou H; Daphnis E; Dendrinos C; Daikos GK
    Drugs Exp Clin Res; 1985; 11(5):351-6. PubMed ID: 2941264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM; Hamilton VE; Thomas MR
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
    Norden CW; Shinners E
    J Infect Dis; 1985 Feb; 151(2):291-4. PubMed ID: 3155780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
    Kemmerich B; Small GJ; Pennington JE
    Antimicrob Agents Chemother; 1986 Mar; 29(3):395-9. PubMed ID: 2940970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
    Moody JA; Gerding DN; Peterson LR
    Am J Med; 1987 Apr; 82(4A):44-54. PubMed ID: 3107380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.
    Eron LJ; Harvey L; Hixon DL; Poretz DM
    Antimicrob Agents Chemother; 1985 Aug; 28(2):308-10. PubMed ID: 2939795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin for Pseudomonas aeruginosa meningitis.
    Millar MR; Bransby-Zachary MA; Tompkins DS; Hawkey PM; Myles Gibson R
    Lancet; 1986 Jun; 1(8493):1325. PubMed ID: 2872448
    [No Abstract]   [Full Text] [Related]  

  • 19. Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.
    Saavedra S; Ramírez-Ronda CH; Nevárez M
    Eur J Clin Microbiol; 1986 Apr; 5(2):255-7. PubMed ID: 2941296
    [No Abstract]   [Full Text] [Related]  

  • 20. Overview of clinical experience with ciprofloxacin.
    Ball AP
    Eur J Clin Microbiol; 1986 Apr; 5(2):214-9. PubMed ID: 3013631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.